EGFR and astrocytoma (excluding glioblastoma): Therefore, in the recent WHO classification proposal, molecular parameters have been added for grading and prognostic estimation, such as homozygous deletion of CDKN2A/B in IDH-mutated astrocytomas, TERT promoter mutation, EGFR amplification and + 7/−10 copy number changes in IDH wild-type diffuse astrocytomas (allowing a glioblastoma designation, even in cases that otherwise appear histologically to be lower grade).